Capacity Worries Fade for Biomanufacturing

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-07-02-2003
Volume 27
Issue 7

The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.

Recent Videos
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Drug Digest: Strategic Partnerships
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content